Generation of CAR-T Cells for Cancer Immunotherapy.

Generation of CAR-T Cells for Cancer Immunotherapy.
Methods Mol Biol. 2019;1884:349-360
Authors: Xu Q, Harto H, Berahovich R, Xu S, Zhou H, Golubovskaya V, Wu L
Abstract
T cells engineered with chimeric antigen receptors (CARs) are emerging as powerful cancer immunotherapies. Remarkable efficacies have been demonstrated in treating B-cell malignancies with CAR-T cells, leading to the FDA's first approval of gene therapy. Currently, numerous clinical trials for hematological malignancies and solid tumors are underway worldwide. Production of CAR-T cells with proper qualities is essential for CAR-T success in vivo. Here we detail optimized protocols for the generation of CAR-T cells for preclinical studies using lentiviral gene transfer, expansion of CAR-T cells in culture, detection of CAR expression, and evaluation of CAR-T cellular cytotoxicity in vitro.
PMID: 30465215 [PubMed - in process]

Source: Mol Biol Cell - November 23, 2018 Category: Molecular Biology Authors: Xu Q, Harto H, Berahovich R, Xu S, Zhou H, Golubovskaya V, Wu L Tags: Methods Mol Biol Source Type: research